Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial

FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer

Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US

G20: Medical Value Travel is an essential component for idealistic healthcare to address disparities of healthcare systems: Kotecha

Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare

AIIMS organises consultation on ‘C2IQ’

For anaemia control in children (0-19 years) & resolves for Call to Action in this direction

ESIC plans to fill 6,400 vacancies including posts for more than 2,000 doctors and teaching faculty: Bhupender Yadav

The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer

This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting

Moderna and Merck announce personalized mRNA cancer vaccine

Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial

Reforms in Ayush to boost growth: Sarbananda Sonowal

Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister

AIIA organises multi-cultural dance competition for Ayurveda Day 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab